European stocks rise as quarterly earnings continue; eurozone retail sales due

European stocks advanced Wednesday, largely supported by a positive Q2 earnings season, although companies are increasingly citing tariff impacts as a potential headwind for Q3. Corporate results were mixed: Novo Nordisk lowered its full-year guidance due to slower weight-loss drug sales, while Siemens Energy expects to hit the upper end of its 2025 growth outlook despite tariffs, and Glencore reported a significant H1 earnings decline driven by commodity price weakness and impairments. Economic data showed a surprising 1% drop in German industrial orders. Concurrently, crude oil rebounded from five-week lows, supported by prospects of tighter U.S. sanctions on Russian oil and a larger-than-expected draw in U.S. inventories.

Analysis

European equity markets are showing resilience, advancing on the back of a generally positive Q2 earnings season. However, this optimism is contrasted by a clear divergence in corporate performance and deteriorating macroeconomic indicators. While companies like Siemens Energy (SIEGn) and Fresenius (FREG) raised their outlooks, citing strong demand in specific divisions, others presented significant headwinds. Novo Nordisk (NVO) notably lowered its full-year guidance due to slowing growth in its high-profile weight-loss drugs, and commodity giant Glencore (GLNCY) posted a steep decline in first-half earnings driven by weaker coal prices and a substantial asset impairment. This corporate-level uncertainty is amplified by a surprise 1% monthly decline in German industrial orders, a key leading indicator that suggests potential difficulty for the upcoming quarter, corroborating corporate warnings about the growing impact of trade tariffs. In the energy market, crude oil has rebounded from a five-week low, supported by a larger-than-expected draw in U.S. inventories and the prospect of tighter sanctions on Russian oil, highlighting an increase in geopolitical risk premium.

Key Decisions for Investors

• Adopt a highly selective, stock-specific approach in European equities, as broad market indices mask significant divergence between winners like Siemens Energy and laggards like Glencore and Novo Nordisk.
• Monitor incoming European macroeconomic data, particularly German indicators and corporate commentary on Q3 tariff impacts, as these pose a direct threat to the current earnings-driven rally.
• Re-evaluate exposure to the pharmaceutical sector, distinguishing between companies with broad-based growth like Fresenius and those facing headwinds in specific, high-growth product lines like Novo Nordisk.
• Factor in heightened geopolitical risk in energy positions, as the recent oil price rebound is driven more by potential supply disruptions and sanctions than by fundamental demand growth.